Other grades of this product :
| KX2-391 Basic information |
| Product Name: | KX2-391 | | Synonyms: | KX 01;5-[4-[2-(4-Morpholinyl)ethoxy]phenyl]-N-(phenylmethyl)-2-pyridineacetamide;N-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetamide;CS-234;KX2-391;KX2 391;KX2391;KX2-391 (KX01);Tirbanibulin, KX2-391;Tirbanibulin | | CAS: | 897016-82-9 | | MF: | C26H29N3O3 | | MW: | 431.53 | | EINECS: | 200-258-5 | | Product Categories: | Inhibitors | | Mol File: | 897016-82-9.mol |
| KX2-391 Chemical Properties |
| Boiling point | 680.9±55.0 °C(Predicted) | | density | 1.169 | | solubility | insoluble in H2O; ≥121 mg/mL in DMSO; ≥2.44 mg/mL in EtOH with gentle warming and ultrasonic | | pka | 14.73±0.46(Predicted) |
| KX2-391 Usage And Synthesis |
| Uses | A synthetic, orally bioavailable small molecule and non-ATP competitive Src tyrosine kinase inhibitor with an IC50 of average 72 nM. | | Uses | KX2-391 is a Src Inhibitor with efficacy against certain hepatic and leukemia cell lines. | | Biological Activity | kx2-391 is a highly selective inhibitor of src kinase with ic50 value of 20nm [1].kx2-391 is a non-atp competitive inhibitor of src. it is the first inhibitor that targets src kinase within the substrate binding site. kx2-391 inhibits src catalyzed trans-phosphorylation of fak, shc, paxillin as well as src kinase autophosphorylation. kx2-391 has no effects on pdgfr, egfr, jak1, jak2 and lck demonstrating it as a selective inhibitor. it is also found to be an inhibitor of tubulin polymerization through binding to the unique confirmation on heterodimeric tubulin. in cellular assays, kx2-391 shows growth inhibition in nih3t3/c-src527f cells and syf/c-src527f cells with gi50 values of 23nm and 39nm, respectively [1, 2].since src acts as a regulator in cell proliferation survival, motility and invasiveness, kx2-391 is potent against a variety of solid tumors and many leukemia tumors. it is shown to inhibit primary tumor growth and to suppress metastasis [2]. | | references | [1] fallah-tafti a, foroumadi a, tiwari r, et al. thiazolyl n-benzyl-substituted acetamide derivatives: synthesis, src kinase inhibitory and anticancer activities. european journal of medicinal chemistry, 2011, 46(10): 4853-4858.[2] naing a, cohen r, dy g k, et al. a phase i trial of kx2-391, a novel non-atp competitive substrate-pocket-directed src inhibitor, in patients with advanced malignancies. investigational new drugs, 2013, 31(4): 967-973. |
| KX2-391 Preparation Products And Raw materials |
|
日本语
한국어
Français
Deutsch
España
Türkiye